



www.MedChemExpress.com

Inhibitors, Agonists, Screening Libraries

CD73

ecto-5'-nucleotidase, NT5E

CD73 (Ecto-5'-nucleotidase), a component of the purinergic signaling pathway, is a 70-kD glycosylphosphatidylinositol-anchored cell surface protein encoded by the NT5E gene.

CD73 has both enzymatic and non-enzymatic functions in cells. As a nucleotidase, CD73 catalyzes the hydrolysis of AMP into adenosine and phosphate, and CD73-generated adenosine plays an important role in tumor immunoescape. CD73 plays a crucial role in switching on adenosinergic signaling. CD73 also functions as a signal and adhesive molecule that can regulate cell interaction with extracellular matrix components, such as laminin and fibronectin, to mediate the invasive and metastatic properties of cancers. Both the enzymatic and non-enzymatic functions of CD73 are involved in cancer-associated processes and are not completely independent of each other.


Overexpression of CD73 is associated with resistance to antitumor agents. Knockdown of CD73 inhibits in vitro cell growth, cell cycle progression and cell migration in many cancers. CD73 and its associated pathways may be useful as therapeutic targets.

CD73 Inhibitors

AB-680

Cat. No.: HY-125286

AB-680 is highly potent, reversible and selective small molecule inhibitor of CD73 (an ecto-nucleotidase), with a K_i of 4.9 pM for hCD73, displays >10,000-fold selectivity over related ecto-nucleotidases CD39. Anti-tumor activity.




Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

CD73-IN-1

Cat. No.: HY-103695

CD73-IN-1 is an inhibitor of CD73 which can be used in the treatment of cancer extracted from patent WO 2017153952 A1, example 80.




Purity: 98.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

CD73-IN-2

Cat. No.: HY-131435

CD73-IN-2 is a potent CD73 inhibitor extracted from WO2020151707A1, example 1, has an IC_{50} of 0.09 nM.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MethADP

(Adenosine 5'-(α,β -methylene)diphosphate)

Cat. No.: HY-112502

MethADP is a specific CD73 inhibitor.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MethADP sodium salt

Cat. No.: HY-112502B

MethADP (sodium salt) is a specific CD73 inhibitor.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

OP-5244

Cat. No.: HY-136978

OP-5244 is a potent and orally bioavailable inhibitor of CD73, with an IC_{50} of 0.25 nM. OP-5244 reverses immunosuppression through blocking of adenosine production, and has the potential for the cancer research.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PSB-12379

Cat. No.: HY-100747

PSB-12379, a nucleotide analogue, is a potent Ecto-5'-Nucleotidase (CD73) inhibitor with K_s of 9.03 nM (rat) and 2.21 nM (human).



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg